levofloxacin has been researched along with novobiocin in 13 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (novobiocin) | Trials (novobiocin) | Recent Studies (post-2010) (novobiocin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 2,271 | 15 | 290 |
| Protein | Taxonomy | levofloxacin (IC50) | novobiocin (IC50) |
|---|---|---|---|
| DNA gyrase subunit B | Mycolicibacterium smegmatis MC2 155 | 0.046 | |
| DNA gyrase subunit B | Staphylococcus aureus | 0.0474 | |
| DNA gyrase subunit B | Streptococcus pneumoniae TIGR4 | 0.037 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.1441 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.1537 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 7.9 | |
| DNA gyrase subunit B | Mycolicibacterium smegmatis | 0.161 | |
| DNA gyrase subunit A | Staphylococcus aureus | 0.0383 | |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 0.0446 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 0.1315 | |
| DNA topoisomerase | Streptococcus pneumoniae | 2.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bist, S; Boriack-Sjodin, PA; Dussault, DD; Fleming, P; Hull, KG; Ioannidis, G; Manchester, JI; Rose, JA; Uria-Nickelsen, M | 1 |
| Basarab, GS; Bist, S; Boriack-Sjodin, PA; Dangel, B; Eakin, AE; Illingworth, R; Manchester, JI; Sherer, BA; Sriram, S; Uria-Nickelsen, M | 1 |
| Basarab, GS; Brassil, P; Doig, P; Galullo, V; Gowravaram, M; Haimes, HB; Kern, G; Kutschke, A; McNulty, J; Schuck, VJ; Stone, G | 1 |
| Amada, H; Endo, M; Hitaka, K; Kamitani, M; Masuko, A; Mihara, Y; Mima, M; Ohtake, N; Sugiyama, H; Takata, I; Takeuchi, T; Tamura, Y; Tanaka-Yamamoto, N; Ushiyama, F; Wada, R | 1 |
| Barker, S; Bennett, JM; Berry, J; Collins, I; Czaplewski, LG; Gamble, V; Haydon, DJ; Lancett, P; Logan, A; Lunniss, CJ; Peasley, H; Pommier, S; Price, D; Smee, C; Stokes, NR; Thomaides-Brears, HB | 1 |
| Ebrahimzadeh, F; Gholami, S; Jafari-Sales, A; Rostami, A; Zadeh, FA | 1 |
2 review(s) available for levofloxacin and novobiocin
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cephalothin; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Bacterial; Furazolidone; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Nalidixic Acid; Nitrofurantoin; Norfloxacin; Novobiocin; Rifampin; Vibrio cholerae; Virulence Factors | 2022 |
11 other study(ies) available for levofloxacin and novobiocin
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
Topics: Adenosine Triphosphatases; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Binding Sites; Crystallography, X-Ray; DNA Gyrase; DNA Topoisomerase IV; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Enzyme Inhibitors; Indoles; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Protein Structure, Tertiary; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2012 |
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Bacteria; Disease Models, Animal; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcal Infections; Structure-Activity Relationship; Topoisomerase II Inhibitors; Urea | 2013 |
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
Topics: Animals; Anti-Bacterial Agents; Barbiturates; Female; Fluoroquinolones; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; Isoxazoles; Male; Mice; Pyridones; Rats, Wistar; Spiro Compounds; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Hep G2 Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Quinolines; Streptococcus pneumoniae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transcriptional Regulator ERG; Vancomycin-Resistant Enterococci | 2020 |
Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Bacterial Proteins; Benzothiazoles; Cell Survival; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Gene Expression; Gram-Negative Bacteria; Gram-Positive Bacteria; Hep G2 Cells; Humans; Interleukin-33; Interleukins; Levofloxacin; Male; Microbial Sensitivity Tests; Novobiocin; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Topoisomerase Inhibitors; Urea | 2013 |